LEGN (Legend Biotech) Rasio Nilai Pasar marang Nilai Buku

Legend Biotech (LEGN) production capacities are operating at peak efficiency, while the expansion of sterile zones allows the company to meet growing demand. The linear price action on the chart confirms the success of Carvykti in the myeloma therapy segment, where the business relies on partnerships with clinics and patients, and the metric stands at 3.19. Long-term profit is based on the ownership of patents for unique treatment methods that have become the indispensable standard.

This metric is calculated as the ratio of the total market capitalization to net equity, measuring the premium of market expectations over the book value of assets. The current value of 3.19 reflects a high valuation of intellectual capital and CAR-T patents, which, combined with strict FDA oversight, makes the dynamics of the market-to-book ratio a key indicator of the investment potential resilience of Legend Biotech (LEGN).